Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report

Frontiers in Oncology

Oncology

Kai Ou¹  Xiaoting Ma¹  Xiu Liu¹  Lin Yang¹  Lizhen Gao²  Manman Zhang² 

[1] Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;Department of Medical Oncology, Beijing Chaoyang Huanxing Cancer Hospital, Beijing, China;

关键词: EGFR;    furmonertinib;    nimotuzumab;    pancreatic cancer;    targeted therapy;   

DOI  :  10.3389/fonc.2023.1151178

 received in 2023-01-25, accepted in 2023-03-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Pancreatic cancer is the leading cause of cancer death, and treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and had disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and observed tumor shrinkage, decreased CA19-9. The progression-free survival (PFS) of furmonertinib was 4.7 months, and no adverse effects were observed. However, the patient did not benefit from subsequent nimotuzumab-based therapy. Targeted therapy driven by the detection of genetic signatures in this patient shows potential clinical benefit in refractory advanced pancreatic cancer.

【 授权许可】

Unknown   
Copyright © 2023 Ma, Liu, Ou, Zhang, Gao and Yang